scholarly journals Thyroid Cancer in Patients with Hyperthyroidism

2015 ◽  
Vol 7 (2) ◽  
pp. 29-32 ◽  
Author(s):  
Baki Tastan ◽  
Alper Dogu ◽  
Yusuf Sevim

ABSTRACT Background and objective Malignant tumors of the thyroid gland are the most common of the endocrine malignancies. Although, patients with thyroid cancer have high 5 years survival rate, thyroid cancer is the most seen cause of mortality among cancers of the endocrine organs. The incidence of thyroid cancer in hyperthyroid patients varies from 0.1 to 21% in the literature. We aimed in this study to analyze the frequency of coexisting thyroid cancer and hyperthyroidism in our experience. Results Total 230 patients, who were operated for hyperthyroidism without the suspicion of thyroid malignancy between January 2005 and September 2010 were included in our study. Toxic multinodular goiter, toxic adenoma and Graves’ disease were diagnosed preoperatively in 187, 16 and 27 patients respectively. Histopathological thyroid malignancy was detected in 13 patients (5.7%). Conclusion Thyroid cancer with variable incidence up to 21% should be remembered in differential diagnosis of hyperthyroid patients. How to cite this article Tastan B, Dogu A, Sevim Y. Thyroid Cancer in Patients with Hyperthyroidism. World J Endoc Surg 2015;7(2):29-32.

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Suemi Marui ◽  
Aline Lenczuk ◽  
Nelisa Helena Rocha ◽  
Tomoco Watanabe ◽  
Luciana Pinto Brito

Abstract INTRODUCTION The diagnosis of Graves′disease (GD) is likely when patient presents hyperthyroidism, symmetrical goiter and orbitopathy and further evaluation is unnecessary. Nevertheless patient with nodular thyroid or in the absence of clinical orbitopathy, measurement of TSH receptor antibodies (TRAb) is recommended to distinguish GD from toxic multinodular goiter, toxic adenoma and other etiologies. Radioiodine uptake (RAIU) also helps to diagnosis when TRAb is unavailable. Third generation TRAb assays measure all types of TSH receptor antibodies: stimulating, blocking and neutral with an excellent sensitivity and specificity for GD diagnosis. Recently, an automated bioassay for the thyroid stimulating immunoglobulin (TSI) was introduced to improve GD diagnosis. OBJECTIVE To analyze clinical performance of TSI and compare with TRAb assay for GD diagnosis. MATERIAL AND METHODS Serum samples of 117 patients with thyrotoxicosis due to GD, toxic multinodular goiter and toxic adenoma were runned simultaneously in two analytical system commercially available. TRAb was analyzed by Elecsys Anti-TSHR assay (Roche Diagnostics, Germany) in a Cobase411 analyzer (Roche Diagnostics, Germany) and results, according to the manufacturer interval reference, were negative if < 1.75 IU/L (analytical range: 0.3 to 40 IU/L). TSI was measured by Immulite TSI assay (Siemens Healthcare, UK) in Immulite XPi 2000 and results, according to the manufacturer interval reference, were negative if < 0.55 IU/L (analytical range: 0.1 to 40 IU/L). Clinical diagnoses of thyrotoxicosis were determined according to ATA guideline (2016). Statistical analyses were performed using SPSS and MedCalc softwares. Comparison were evaluated by regression equations and were considered significant when p values were < .05. RESULTS From 2017 to 2019 a total of 312 serum samples from 117 patients (96 females) were evaluated with mean age 49.5 ±15.8 years-old (18 to 90 yrs). We excluded 26 results above the analytical measurement range of both assays. A high degree correlation was observed with a slope of 0.647 and an intercept -.094 IU/L. Spearman correlation coefficient was 0.858 (p < 0.0001, 95% CI 0.825 to 0.886). TSI assay had higher sensibility and negative predictive value compared to TRAb (95.6% vs 88.5% and 83.6% vs 54.8%, respectively) but lower specificity and positive predictive value (90.3% vs 100% and 97.5% vs 100%, respectively). The results of TSI assay showed good agreement with those of the TRAb assay (k=0.74). A total of 31 samples were discordant, favoring to TSI assay in all but one case of GD according to clinical diagnosis (TRAb positive and TSI negative). CONCLUSION TSI assay showed an excellent performance for GD diagnosis with a better sensibility than TRAb assay.


2021 ◽  
Vol 4 (1) ◽  
pp. 48
Author(s):  
Rizki Adrian Hakim ◽  
Stepanus Massora ◽  
Delfitri Lutfi ◽  
Hermina Novida

Graves’ Disease (GD) is the most common etiology of thyrotoxicosis, followed by toxic multinodular goiter and toxic adenoma. GD can be managed with anti-thyroid drugs (ATDs), surgery, or radioactive iodine (RAI). Thyroid-associated orbitopathy (TAO) or Graves’ Ophthalmopathy (GO) affects 25%-50% patients with GD, and its presence usually dissuade clinicians to use RAI in treating hyperthyroidism. The presence of GO is a relative contraindication use of RAI in patients with GD, as RAI can worsen existing GO. Corticosteroid prophylaxis can be given to such patients to reduce likelihood of worsening of GO. However, patient with moderate to severe active GO is currently advised against undergoing RAI. Established guidelines recommend the use of corticosteroid prophylaxis in these patients. We reported a patients with GD and orbitopathy who was treated with RAI and was given steroid prophylaxis to prevent worsening of GO.


Author(s):  
Ali Pooria ◽  
Afsoun Pourya ◽  
Alireza Gheini

Background: Hyperthyroidism is a common systemic disorder where Graves’ disease is known as the leading cause of the disease. Thyroid stimulating hormone, T4 and T3 antibody assay are usually performed for the diagnosis of the pathology. However, with uncertainty in the results and in order to estimate the magnitude and the exact cause of the disease, radioactive iodine uptake (RAIU) test is recommended. The aim of this study is to evaluate underlying pathology in the patients presenting hyperthyroidism using RAIU test results. Methods: This is a cross-sectional retrospective study conducted on the patients with hyperthyroidism referred to Shahid Madani Hospital in Khorramabad. Data regarding the biochemical analysis and RAIU test was collected from the records and a questionnaire based on demographic and clinical information was completed for each patient. Results: Of 137 patients presenting hyperthyroidism, 62.04% were presented with Graves’ disease, 24.08% with toxic multinodular goiter and 13.86% with toxic adenoma. 24-hour RAIU test showed that the percent of radioiodine uptake was most in toxic adenoma 67.7%, Graves’ disease 53.5% and multinodular goiter 39%, respectively. From the age-based analysis, we found that Graves’ was most common in 20-30 years old individuals 34%, multinodular goiter in 50+ aged individuals 36.3% and toxic adenoma was most prevalent in 30-40 and 50+ aged patients, 26.3% each. In our population of interest, 81.8% toxic multinodular goiter patients were females. Conclusions: Our study presents the outcome of RAIU tests in hyperthyroidism based on the underlying pathologies. We also conclude, in light of other findings, Graves’ disease is the most common cause of hyperthyroidism in our population.


Surgery ◽  
2008 ◽  
Vol 144 (6) ◽  
pp. 1028-1037 ◽  
Author(s):  
Yasemin Giles (Senyurek) ◽  
Tunca Fatih ◽  
Boztepe Harika ◽  
Kapran Yersu ◽  
Terzioglu Tarik ◽  
...  

2016 ◽  
Vol 8 (1) ◽  
pp. 50
Author(s):  
Saleha Sultana ◽  
Syed Abdul Wadud ◽  
Shabeena Huda ◽  
Sharfuddin Ahmed

<p><strong>Background:</strong> The eye changes associated with thyroid disease are referred to as Thyroid related Orbitopathy. A well described association exist between open angle glaucoma and thyroid related orbitopathy, the possible relationship between open angle glaucoma and either hypothyroidism or hyperthyroidism without orbitopathy is variable.</p><p><strong>Objective:</strong> To observe the relation of open angle glaucoma (OAG), glaucoma suspect (GS) and ocular hypertension(OHT) between Thyroid related immune orbitopathy (TRIO) and other thyroid diseases (toxic multinodular goiter and hypothyroidism).</p><p><strong>Method:</strong> With purposive type of sampling technique 40 patients of Graves' disease disease in Group-A and 40 patients of other thyroid diseases in Group-B which was subdivided into 20 patients of toxic multinodular goiter in Group-B 1, 20 patients of hypothyroidism in Group-B2 were selected in Bangabandhu Sheikh Mujib Medical University (BSMMU) for this cross sectional study. The diagnosis of Graves' disease, toxic multinodular goiter and hypothyroidism were carried out by history, clinical examination and clinical test in endocrinology department. All the patients underwent complete ocular examinations, measuring of intraocular pressure (IOP), fundus examination, visual field analysis, gonioscopy and exophthalmometry.</p><p><strong>Result:</strong> The OAG, GS and OHT was 7.5% (3 cases), 5.0% (2 cases) and 17.5% (7 cases) respectively in Group-A. In contrast OAG, GS was 5% (lease), 5% (1 case) respectively in Group-Bl, only 5% (1 case) OAG in Group-B2. There was no incidence of OHT in Group-B (B1+B2). Although the occurrence of OAG and GS were higher in Group-A than Group-B, this difference was not statistically significant (p&gt;0.05). However OHT was more common in Group-A than Group-B and is statistically significant (p&lt;0.05). Among the 12 patients with OAG, GS and OHT in Group-A, 11 had ≥22mm exophthalmos. In Group-A, ≥22mm exophthalmos in 60% cases, in contrast none of Group-B have ≥22mm.</p><p><strong>Conclusion:</strong> The occurrence of OHT was higher in thyroid related immune orbitopathy than other thyroid diseases.</p>


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Rodis Paparodis ◽  
Karvounis Evaggelos ◽  
Dimitra Bantouna ◽  
Charilaos Chourpiliadis ◽  
Hourpiliadi Hara ◽  
...  

Abstract Introduction: Incidental finding of differentiated thyroid microcarcinomas (DTMc) in patients with thyroid nodules, undergoing thyroid surgery for benign indications, have become increasingly common. Even though carcinogenesis might relate to the background disease of the gland, the incidence of DTMc in the setting of various thyroid disorders remains unclear. We designed the present study to address this question. Methods/ Subjects: We reviewed the data from two prospectively collected databases of patients undergoing thyroid surgery in two high-volume tertiary care referral centers, one in the USA (A) and the other one in Greece (B) over 14 consecutive years. We collected data on the preoperative surgical indication, FNA cytology and surgical pathology. We excluded subjects operated for thyroid cancer or indications at high risk for malignancy (FNA suspicious for thyroid cancer, follicular neoplasm, suspicious for follicular neoplasm, FLUS/AUS, cellular specimen or sonographic features of malignancy), and those with post-surgical pathology consistent with PTC &gt;9mm in largest diameter. We split our subjects based on pathology data in those with chronic lymphocytic thyroiditis (CLT), Graves disease (GR) or multinodular goiter (MNG). Incidence of DTMc or features of tumor aggressiveness were compared among groups, using Fischer’ s exact test and odds ratios (OR) were calculated. Categorical values were compared with Kruskal Wallis test. P values &lt;0.05 were deemed significant. Results: We reviewed 6096 cases of thyroid surgery (A:2711, B:3385). We included 3909 subjects. Overall 609 (15.6%) DTMc were identified [A:256/2003 (12.8%), B:353/1906(18.5%) OR 0.79, p&lt;0.0001]. CLT was present in 626 subjects; where DTMc was present in 155 (24.8%) [A:83/410 (20.2%), B: 72/216 (33.3%), OR 0.51 p&lt;0.001]. GR was present in 377 subjects; where DTMc was present in 39 (10.3%) subjects [A:14/209 (6.7%) B: 25/168 (14.9%) OR 0.41, p=0.01]. MNG was present in 1964 subjects; where DTMc was present in 314 (15.9%) subjects [A: 58/686 (8.5%), B:256/1278 (20.0%)]. The incidence of DTMc was significantly higher in CLT compared to MNG (OR 1.73) or GR (OR 2.85) (p&lt;0.001 for both) and in MNG compared to GR (OR 1.64, p=0.0064). Maximal tumor diameter was not significantly different among groups (CLT 0.46cm, MNG 0.44cm, GR 0.44cm, p=0.56). Conclusions: Incidentally discovered differentiated thyroid microcarcinomas are more commonly identified in surgical specimens from subjects with chronic lymphocytic thyroiditis as compared to patients with multinodular goiter, while patients with Graves' disease present with a much smaller incidence compared to both groups. This data supports previously published findings that euthyroid Hashimoto thyroiditis could allow for carcinogenesis, while Graves disease could have a protective role.


2007 ◽  
Vol 53 (3) ◽  
pp. 157 ◽  
Author(s):  
C Cerci ◽  
SS Cerci ◽  
E Eroglu ◽  
M Dede ◽  
N Kapucuoglu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document